Ampio Pharmaceuticals is a Colorado-based biopharmaceutical company that develops immunomodulatory therapies for pain in osteoarthritis in the US. They have a product pipeline including AP-013 (in Phase III clinical trial for knee osteoarthritis), AP-017 (in Phase II clinical trial for COVID-19 patients), AP-019 (in Phase II clinical trial for COVID-19 respiratory distress) and AP-018 (in Phase I clinical trial to treat respiratory symptoms in COVID-19 patients). The company is primarily focused on these treatments.